Citizens Reiterates Market Outperform on Compass Therapeutics, Maintains $10 Price Target

Benzinga Newsdesk www.benzinga.com Negative 91.4%

Neg 91.4% Neu 0% Pos 0%

Citizens analyst Reni J. Benjamin reiterates Compass Therapeutics (NASDAQ:CMPX) with a Market Outperform and maintains $10 price target.